Abstract:Nathaniel Deboever, Mara B. Antonoff Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA Comment on: Zhao ZR, Lin ZC, Shen JF, et al . Neoadjuvant Immunotherapy in Oncogene-Positive Non-Small Cell Lung Cancer: A Multicenter Study. Ann Thorac Surg 2023;116:703-10. Keywords: Lung cancer; immunotherapy; oncogene-positive lung cancer Submitted Dec 18, 2023. Accepted for publication Mar 04, 2024. Published online Apr 23, 2024. doi: 10.21037/jtd-23-1918 The utilization of immune-checkpoint inhibitor (ICI) in conjunction with chemotherapy has excitingly and consistently demonstrated a survival advantage in individuals with resectable non-small cell lung cancer (NSCLC). These findings stem from various recently completed randomized clinical trials (1-4), which have not only established the efficacy of such combined therapeutic approaches but have also contributed to a deeper understanding of factors associated with potentially more pronounced responses to systemic therapy. Notably, the presence of targetable oncogenic drivers in NSCLC, such as mutations in the epidermal growth factor receptor (EGFR) gene or translocations in the anaplastic lymphoma kinase (ALK) gene, have been identified as such factors. Understanding these relationships can optimize therapy for a substantial number of patients, as the former aberration can be detected in up to 17% of early-stage NSCLC cases (5). Targeted therapy for oncogene-positive disease has demonstrated a survival benefit, as evidenced by studies like ADAURA (6). However, the use of immunotherapy in patients with mutations has not been extensively explored (7). For instance, the KEYNOTE-671 trial encompassed patients with stage II to IIIB resectable NSCLC, with or without oncogene-positive disease, managed with perioperative pembrolizumab vs. placebo; only 33 patients (4.1%) with known EGFR mutations and 21 patients (2.6%) with known ALK translocations were included (2). Notably, patients with known EGFR mutations exhibited a more substantial benefit from receiving pembrolizumab [hazard ratio (HR) for event-free survival: 0.09, 95% confidence interval (CI): 0.01–0.74]. Conversely, adjuvant ICI was more beneficial in patients lacking ALK translocations (HR: 0.41, 95% CI: 0.26–0.62). In the PEARLS/KEYNOTE-091 trial, patients with IB to IIIA resectable NSCLC were randomized to receive pembrolizumab vs. placebo in the adjuvant setting, among whom 73 patients (6.2%) had known EGFR mutations and 14 patients (1.2%) had known ALK translocations (8). Once again, patients with known EGFR mutations responded positively (HR for disease-free survival: 0.44, 95% CI: 0.23–0.84) to pembrolizumab in the adjuvant setting compared to patients without a mutation (HR: 0.78, 95% CI: 0.59–1.05) or those with an unknown mutation status (HR: 0.82, 95% CI: 0.63–1.05). The utilization of immunotherapy in patients with stage IV NSCLC and targetable mutations has been scrutinized, revealing an association with elevated adverse events and a lack of meaningful survival benefit. In the TATTON study, a multi-arm phase IB trial, patients with advanced NSCLC and EGFR mutations were randomized to receive various combination therapies, including osimertinib [tyrosine kinase inhibitor (TKI)] with durvalumab (immune-checkpoint blockade) (9). Within this treatment group, 5 out of 23 (21.7%) patients developed interstitial lung disease. The sequential administration of ICI in patients with advanced oncogene-positive NSCLC has traditionally been linked to severe immune-related adverse events, leading to the current recommendation against this therapeutic approach (10,11), rather, encouraging the use of biomarker testing and targeted agents as first line (12). Despite the available data regarding adjuvant ICI use in patients with resectable early-stage NSCLC and oncogene-positive disease or in patients with metastatic disease, there is a deficiency in level 1 evidence regarding its application in this population in the neoadjuvant setting. For instance, the pivotal Checkmate-816 trial enrolled patients with IB to IIIA resectable NSCLC but excluded those with known ALK translocations or EGFR mutations (1). Recently, Zhao and colleagues conducted a multicenter study aiming to explore the neoadjuvant immunotherapeutic benefits in patients with resectable oncogene-positive NSCLC (13). The authors retrospectively reviewed four institutions, identifying 137 patients with stage IIA to IIIB resectable NSCLC who received neoadjuvant ICI or combination chemotherapy-ICI. Stratification was performed based on oncogene status, encompassing EGFR mutations, ALK translocations or mutations, KRAS mutations, MET amplifications or mutations, BRAF mutations, ROS1 rearrangements or mutations, and RET fusions. PD-1 blockade monotherapy (nivolumab or pembrolizumab) or combinati -Abstract Truncated-

Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer

Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study

The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC.

Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small Cell Lung Cancer: a Case Report

The Safety and Efficacy of Immune Checkpoint Inhibitor in Combination with FOLFOX As Neoadjuvant/adjuvant Therapy in Patients with Locally Advanced Colon Cancer.

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Neoadjuvant Immunotherapy or Chemoimmunotherapy in Non-Small Cell Lung Cancer: a Systematic Review and Meta-Analysis

467 Phase II Clinical Study of Toripalimab in Combination with Stereotactic Radiotherapy As a Neoadjuvant Therapy for the Treatment of Resectable (N1-N2) Non-Small Cell Lung Cancer

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art

Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer

[Application of Neoadjuvant Immuno-chemotherapy in NSCLC].

Neoadjuvant Programmed Cell Death Protein 1 Blockade Combined With Stereotactic Body Radiation Therapy for Stage III(N2) Non-Small Cell Lung Cancer: A Case Series

Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?

Efficacy and safety of perioperative, neoadjuvant, or adjuvant immunotherapy alone or in combination with chemotherapy in early-stage non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials

Efficacy and Safety of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer: a Systematic Review and Meta-Analysis

Immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer: a systematic review and meta-analysis

[Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].

Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives

Global implementation of individualized lung cancer care requires wide adoption of molecular tumor profiling

The efficacy and safety of neoadjuvant anti-PD-1 inhibitor combined with platinum-based chemotherapy in patients with potentially resectable non-small cell lung cancer.

Neoadjuvant Chemoimmunotherapy for NSCLC